Funded Tech Companies
EG 427
Researching who provided funding to EG 427? Private investors joined the equity holders in this biopharmaceutical company.
Company Overview
Company Name
EG 427
Company Status
Private & Independent
Industry
Funding Rounds
Total Funding
Contact Information
Mailing Address
29 rue du Faubourg Saint-Jacques
Paris, 75014
FR
Paris, 75014
FR
Phone
Undisclosed
Website
Email Address
Company Background Information
Overview
EG 427 is a French biotechnology company that is pioneering a new approach called pinpoint gene therapy. Our unique, non-replicative Herpes Simplex Virus type 1 (HSV-1) based vector platform delivers, with pinpoint precision, highly selective, durable expression of disease modifying transgenes for use in the treatment of peripheral nervous system disorders and beyond. Our research capability is focussed on ensuring our powerful platform approach has wide applicability, with potential for many products across several therapeutic areas with severe unmet medical needs.
Profile
Social Media
Company News
Facebook
YouTube
Last Transaction
7/13/2023
Financing History
Date
Type
Amount
Management Team
Title
Name
Email & Social
Chief Executive Officer
Philippe Chambon
Chief Marketing Officer
Cornelia Molkenteller
Chief Operating Officer
Samuel Salot
Chief Scientific Officer
Alberto Epstein
Co-Founder
François Giuliano
Company Investors
Browse more funded tech companies:
Share this article
About Our Venture Capital Database
This tech company profile is powered by VentureDeal.com, a leading provider of venture capital transaction data.
Additional Resources for Entrepreneurs